GOSERELIN

Information current as at: 1 September 2026

PBAC meeting date: September 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Zoladex®
Form and strength:
  • Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre-filled injection syringe
Submission sponsor:
ASTRAZENECA PTY LTD
Condition/indication:
(therapeutic use)
  • To consider a request for the listing of goserelin subcutaneous implant (long acting) 10.8 mg (as acetate) in pre-filled injection syringe for the treatment of hormone receptor positive (HR+) breast cancer.
Listing requested:
Please see PSD for more information
Funding program:
PBS General Schedule
Request authority level:
Restricted Benefit
PBAC Submission type:
Change to existing listing (Category 2)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
September 2026 PBAC meeting
2Opportunity for consumer comment:
Open 28/08/2026 and close 02/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1318
Page last updated
31 August 2026
Return to the Medicine Status Listing
v.9.19